Happiness Biotech Group Limited Net Income | HAPP

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Happiness Biotech Group Limited

2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-12.7 M	-7.89 M	-10.1 M	-71.7 M	-48.8 M	786 K	12.7 M	18.7 M	17.5 M	14.5 M	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
18.7 M	-71.7 M	-8.71 M

Quarterly Net Income Happiness Biotech Group Limited

2026-Q4	2026-Q2	2025-Q2	2025-Q1	2024-Q4	2024-Q1	2023-Q4	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-681 K	-1.77 M	-7.89 M	-	-10.1 M	-	-19.4 M	-71.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-681 K	-71.7 M	-18.6 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
ContraFect Corporation CFRX	-65.2 M	-	-5.16 %	$ 5.39 M	USA
Turning Point Therapeutics TPTX	-237 M	-	-0.13 %	$ 3.73 B	USA
Epizyme EPZM	-251 M	-	-	$ 249 M	USA
Forward Pharma A/S FWP	-1.89 M	-	-0.75 %	$ 18.7 M	Danmark
Gamida Cell Ltd. GMDA	-72.7 M	-	-18.25 %	$ 5.04 M	Israel
Regulus Therapeutics RGLS	-46.4 M	-	-	$ 155 M	USA
Marinus Pharmaceuticals MRNS	-141 M	-	-	$ 29.6 M	USA
NeuBase Therapeutics NBSE	-4.37 M	-	-1.56 %	$ 12.3 M	USA
Arena Pharmaceuticals ARNA	-616 M	-	-6.81 %	$ 3.04 B	USA
Scopus BioPharma SCPS	-11.6 M	-	-48.37 %	$ 3.71 M	USA
scPharmaceuticals SCPH	-85.1 M	-	-	$ 218 M	USA
Athersys ATHX	-72.5 M	-	3.77 %	$ 22.4 M	USA
Seagen SGEN	-610 M	-	-	$ 42.2 B	USA
Sigilon Therapeutics SGTX	-43.6 M	-	-	$ 728 M	USA
Rubius Therapeutics RUBY	-180 M	-	-33.55 %	$ 7.81 M	USA
TRACON Pharmaceuticals TCON	-3.59 M	-	-1.38 %	$ 46.8 M	USA
Revance Therapeutics RVNC	-324 M	-	-	$ 309 M	USA
Sierra Oncology SRRA	-94.7 M	-	-0.05 %	$ 1.34 B	Canada
Vaccinex VCNX	-18.6 M	-	-61.37 %	$ 654 K	USA
Forma Therapeutics Holdings FMTX	-173 M	-	-	$ 958 M	USA
Bellicum Pharmaceuticals BLCM	-25 M	-	-9.72 %	$ 5.89 M	USA
Blueprint Medicines Corporation BPMC	-67.1 M	-	-	$ 8.14 B	USA
Paratek Pharmaceuticals PRTK	-63.6 M	-	-	$ 121 M	USA
ASLAN Pharmaceuticals Limited ASLN	-44.2 M	-	-14.27 %	$ 1.7 M	Singapore
Acorda Therapeutics ACOR	-253 M	-	-24.86 %	$ 820 K	USA
Ampio Pharmaceuticals AMPE	-8.63 M	-	-11.43 %	$ 502 K	USA
Nabriva Therapeutics plc NBRV	-57.2 M	-	-	$ 4.55 M	Irlanda
NGM Biopharmaceuticals NGM	-142 M	-	-	$ 127 M	USA
Unity Biotechnology UBX	-26 M	-	-33.41 %	$ 3.37 M	USA
Aravive ARAV	-76.3 M	-	-13.39 %	$ 1.45 M	USA
Titan Pharmaceuticals TTNP	-4.71 M	-	-3.76 %	$ 3.47 M	USA
iTeos Therapeutics ITOS	-134 M	-	-	$ 411 M	USA
Allena Pharmaceuticals ALNA	-10.4 M	-	3.16 %	$ 1.9 M	USA
Alpine Immune Sciences ALPN	-32.2 M	-	-	$ 2.17 B	USA
TCR2 Therapeutics TCRR	-152 M	-	-	$ 58.1 M	USA
CymaBay Therapeutics CBAY	-105 M	-	-	$ 3.45 B	USA
Aridis Pharmaceuticals ARDS	-30.4 M	-	17.91 %	$ 11.1 M	USA
TFF Pharmaceuticals TFFP	-21.2 M	-	-60.05 %	$ 125 K	USA
Theratechnologies THTX	-31.7 M	-	-	$ 83.9 M	Canada
Timber Pharmaceuticals TMBR	-19.4 M	-	-	$ 717 K	USA
Adaptimmune Therapeutics plc ADAP	-70.8 M	-	-15.15 %	$ 60.3 M	Britain
Advaxis ADXS	-48.1 M	-	-9.65 %	$ 45.9 M	USA
Axcella Health AXLA	-81.2 M	-	-16.42 %	$ 249 M	USA
Tyme Technologies TYME	-23.6 M	-	8.07 %	$ 54 M	USA
Vascular Biogenics Ltd. VBLT	-11.3 M	-	-8.77 %	$ 12.4 M	Israel
Berkeley Lights BLI	-98 M	-	-7.31 %	$ 87 M	USA
Codiak BioSciences CDAK	-37.2 M	-	-55.98 %	$ 2.15 M	USA
Cerevel Therapeutics Holdings CERE	-433 M	-	-	$ 7.29 B	USA
Checkpoint Therapeutics CKPT	-56.2 M	-	-	$ 169 M	USA
Sage Therapeutics SAGE	-401 M	-	-	$ 527 M	USA